Navigation Links
Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
Date:3/16/2009

50 percent were achieved in 78 percent of evaluable patients who received the picoplatin combination. In addition, interim analysis revealed that the median time to PSA progression was 8.5 months with the picoplatin combination. In this study, patients were treated with picoplatin therapy for up to 10 cycles and up to a picoplatin cumulative dose of 1200 mg. Safety results continued to demonstrate that picoplatin can be safely administered with full doses of docetaxel and prednisone, the standard treatment for metastatic CRPC, supporting the use of this combination in future clinical trials.

  • Colorectal Cancer: In January 2009, the Company presented interim efficacy and safety data from its ongoing, randomized, controlled Phase 2 clinical trial of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) in patients with metastatic colorectal cancer (CRC) at the ASCO 2009 Gastrointestinal Cancers Symposium. Results continued to show that picoplatin, given once every four weeks in the FOLPI regimen, was associated with less frequent and less severe neurotoxicity than the FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) regimen, where oxaliplatin has shown treatment-limiting neurotoxicity. Results also continue to indicate that both FOLPI and FOLFOX regimens have similar anti-tumor activity as a first-line treatment for metastatic CRC, supporting the potential use of picoplatin as a neuropathy-sparing alternative to oxaliplatin.

  • Oral Picoplatin: In November, the Company announced top-line results from a Phase 1 clinical trial of an oral formulation of picoplatin in patients with solid tumors. These results indicated that picoplatin achieves linear and dose-dependent plasma exposure when given by the oral route, indicating sufficient bioavailability to support further clinical development of an oral formulation of the drug.
    '/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  SI-BONE, Inc. ( San Jose, California ... use of the iFuse Implant System, ® a ... the sacroiliac (SI) joint, announced that Priority Health ( ... Lumbar Fusion Medical Policy No. 91590-R4 providing positive coverage ... states that the fusion procedure, which employs the iFuse ...
(Date:8/20/2014)... 20, 2014 Northstar Global Business Services, ... months of hard work from many talented specialists, ... formulation and package design.  The new formulation for ... into the product due to overwhelming evidence of ... Snorenz Nighttime will also include these vitamins, as ...
(Date:8/20/2014)... 20, 2014 The National Association of ... results achieved by the real-time, pseudoephedrine (PSE) blocking ... Precursor Log Exchange (NPLEx), automatically blocks unlawful pseudoephedrine ... meth offenders and make arrests. Data released by ... blocked the sale of more than ...
Breaking Medicine Technology:SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Northstar completes the first phase of its new retail strategy and prepares to ship reformulated Snorenz with all new packaging 2Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... , MINNETONKA, Minn. , July 14 ... a leading provider of world-class devices and therapies for both ... prospective, multi-center study on their market leading MiniArc Single-Incision Sling ... concludes that MiniArc efficacy rates for negative cough stress test ...
... CINCINNATI , July 14 Kendle (Nasdaq: KNDL ) announced today ... Wednesday, Aug. 4, 2010 . The Company will host a telephone conference call and simultaneous ... question and answer session will follow. , , ... , , , ...
Cached Medicine Technology:12-Month Study Reports 90% Success Rate for AMS' MiniArc Single-Incision Sling 212-Month Study Reports 90% Success Rate for AMS' MiniArc Single-Incision Sling 3Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast 2Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast 3
(Date:8/21/2014)... 2014 Entries are now open for ... comprehensive national awards program totally dedicated to recognizing excellence ... executive leadership. The entry deadline is Oct. 17. , ... Insights™, the first and only national magazine entirely devoted ... , “We launched the HREI Insights Awards program last ...
(Date:8/21/2014)... New York, New York (PRWEB) August 21, 2014 ... the Medical Cannabis Network that a company located in ... to be the only marijuana patient verification ... like to welcome this new entity to our growing ... due to our belief that these claims are inaccurate. ...
(Date:8/21/2014)... Steven Reinberg HealthDay Reporter ... experimental drug shows promise in treating respiratory syncytial virus (RSV), ... "We are finally making major progress in being able to ... of serious viral pneumonia, second only to influenza virus," said ... the University of Tennessee College of Medicine in Memphis. ...
(Date:8/21/2014)... ATLANTAStrongly influenced by their self-interest, humans do not ... consequences, researchers in Georgia State University,s Brains and ... that humans are less concerned than previously believed ... findings are published in the journal Brain ... unfairness is affected by their self-interest, indicating the ...
(Date:8/21/2014)... 21, 2014 Competing in the “Best ... Greg” will screen on Monday, August 25th at 7 ... Film Festival. This festival is named in top festival ... Symphony, Sony Software, Avid, and Write Brothers. , The ... & LFX, located at 410 South Myrtle Avenue (showtimes: ...
Breaking Medicine News(10 mins):Health News:Entries Open for 2014 HREI Insights Awards™ 2Health News:Entries Open for 2014 HREI Insights Awards™ 3Health News:Entries Open for 2014 HREI Insights Awards™ 4Health News:MarijuanaDoctors.com Responds to Massachusetts Company's Claim 2Health News:New Drug May Fight Serious Respiratory Virus in Infants 2Health News:New Drug May Fight Serious Respiratory Virus in Infants 3Health News:Influenced by self-interest, humans less concerned about inequity to others 2Health News:Influenced by self-interest, humans less concerned about inequity to others 3Health News:“Heavy Metal Greg,” a Music Talk Show by Gregory Graham, Will Screen at Action on Film International Film Festival on 08/25/2014 2
... begin meeting the ... on Monday, BOLINGBROOK, Ill., Jan. 11 The ... will officially open its doors on Monday,January 14. After ... and facility reviews from the Illinois,Department of Public Health ...
... to improve results, study says , , FRIDAY, Jan. ... allowing for spontaneous breathing -- the so-called "wake ... mechanical ventilators in intensive care units, a new ... from ventilators and should become common practice, the ...
... of antibodies may block human immunodeficiency virus (HIV)-1 infection ... HIV-1 vaccine. The findings, published by Cell Press in ... antibody induction appears to be a key and necessary ... recent failure of vaccines that stimulated only the T ...
... 11 Welcome to Consumer,Reports Health News ... ConsumerReports.org cover issues pertaining to the efficacy ... natural medicines),mental health, diet and nutrition, food ... products, rates the effectiveness and affordability of,prescription ...
... Health loss caused by type 2 diabetes will more ... most other major causes falls, according to new research ... The research, published in the January 7 edition of ... of disease and injury in Australia from 1993 to ...
... Life Brokerage Partners,announces three new carrier relationships ... With these new additions, Life Brokerage,Partners provides ... of the most,exclusive national insurance carriers and ... agency., New relationships with Midland National, ...
Cached Medicine News:Health News:Adventist Bolingbrook Hospital Opens to the Public 2Health News:Dual Treatment Helps Wean Patients From Ventilators 2Health News:Dual Treatment Helps Wean Patients From Ventilators 3Health News:Uncovering the Achilles' heel of the HIV-1 envelope 2Health News:Consumer Reports Health News 2Health News:Consumer Reports Health News 3Health News:Consumer Reports Health News 4Health News:UQ research predicts type 2 diabetes explosion 2Health News:Life Brokerage Partners Adds New Insurance Carriers 2
Redesigning the World's Oxygen Therapy One Device at a Time. , ,Everything you like about our OXYMATIC 400 Series conservers, only better!...
... Accutrol is similar in design to the ... incorporates a temperature probe at the tip ... can accurately determine the patient's core body ... accuracy comparable to a pulmonary artery catheter ...
... Ultra Micro Shafts For Insertion Through ... For Light-Weight ... ,Curved Shafts For A More Comfortable Approach., ... ,Protective Cap Supplied For Protection Of Jaws ...
The New Easy-To-Use Disposable Diamond Knife Cleaning System Can Remove Even Baked-On Debris In Seconds. It Is Much More Effective Than Steam Or Blocks Of Styrofoam, Much Safer For Employees As Wel...
Medicine Products: